Outcome determinants of fusariosis in a tertiary care cancer center: The impact of neutrophil recovery

被引：38

作者：

Kontoyiannis, DP ^{[1
]}

Bodey, GP ^{[1
]}

Hanna, H ^{[1
]}

Hachem, R ^{[1
]}

Boktour, M ^{[1
]}

Girgaway, E ^{[1
]}

Mardani, M ^{[1
]}

Raad, II ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA

来源：

LEUKEMIA & LYMPHOMA | 2004年 / 45卷 / 01期

关键词：

fusariosis; neutropenia; outcome;

D O I：

10.1080/1042819031000149386

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Factors associated with failure of antifungal therapy were examined in 42 cancer patients with fusariosis (1987 - 1997). Thirty-six patients (86%) had leukemia and 39 (93%) were neutropenic. Disseminated infection was the most common presentation. The majority (83%) received amphotericin B-based therapy. Thirty patients (71%) failed therapy. No patient with persistent neutropenia responded.

引用

页码：139 / 141

页数：3

共 12 条

[1] EFFECTIVENESS OF AN ORAL TRIAZOLE FOR OPPORTUNISTIC MOLD INFECTIONS IN PATIENTS WITH CANCER - EXPERIENCE WITH SCH-39304 [J].

ANAISSIE, EJ ;

KONTOYIANNIS, DP ;

VARTIVARIAN, S ;

KANTARJIAN, HM ;

OBRIEN, S ;

GIRALT, SA ;

ANDERSSON, BS ;

KARL, C ;

CHAMPLIN, RE ;

BODEY, GP .

CLINICAL INFECTIOUS DISEASES, 1993, 17 (06) :1022-1031

[2] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].

Ascioglu, S ;

Rex, JH ;

de Pauw, B ;

Bennett, JE ;

Bille, J ;

Crokaert, F ;

Denning, DW ;

Donnelly, JP ;

Edwards, JE ;

Erjavec, Z ;

Fiere, D ;

Lortholary, O ;

Maertens, J ;

Meis, JF ;

Patterson, TF ;

Ritter, J ;

Selleslag, D ;

Shah, PM ;

Stevens, DA ;

Walsh, TJ .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14

[3] Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management [J].

Boutati, EI ;

Anaissie, EJ .

BLOOD, 1997, 90 (03) :999-1008

[4] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].

Denning, DW ;

Ribaud, P ;

Milpied, N ;

Caillot, D ;

Herbrecht, R ;

Thiel, E ;

Haas, A ;

Ruhnke, M ;

Lode, H .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571

[5]

HACHEM RY, 2000, 40 INT C ANT AG CHEM, pJ1109

[6]

MAERTENS J, 2002, 41 INT C ANT AG CHEM, pM860

[7] TAXONOMY, BIOLOGY, AND CLINICAL ASPECTS OF FUSARIUM SPECIES [J].

NELSON, PE ;

DIGNANI, MC ;

ANAISSIE, EJ .

CLINICAL MICROBIOLOGY REVIEWS, 1994, 7 (04) :479-&

[8]

Torres HA, 2003, OXFORD TXB CLIN MYCO, P252

[9] Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children [J].

Walsh, TJ ;

Lutsar, I ;

Driscoll, T ;

Dupont, B ;

Roden, M ;

Ghahramani, P ;

Hodges, M ;

Groll, AH ;

Perfect, JR .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (03) :240-248

[10] PCR AND SINGLE-STRAND CONFORMATIONAL POLYMORPHISM FOR RECOGNITION OF MEDICALLY IMPORTANT OPPORTUNISTIC FUNGI [J].

WALSH, TJ ;

FRANCESCONI, A ;

KASAI, M ;

CHANOCK, SJ .

JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (12) :3216-3220

← 1 2 →